- Home
- BMRA vs AYTU Comparison
BMRA vs AYTU Comparison
Compare BMRA & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- AYTU
- Stock Information
- Founded
- BMRA 1971
- AYTU N/A
- Country
- BMRA United States
- AYTU United States
- Employees
- BMRA N/A
- AYTU N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- BMRA Health Care
- AYTU Health Care
- Exchange
- BMRA Nasdaq
- AYTU Nasdaq
- Market Cap
- BMRA 8.1M
- AYTU 9.6M
- IPO Year
- BMRA N/A
- AYTU N/A
- Fundamental
- Price
- BMRA $3.91
- AYTU $2.63
- Analyst Decision
- BMRA
- AYTU Strong Buy
- Analyst Count
- BMRA 0
- AYTU 2
- Target Price
- BMRA N/A
- AYTU $10.00
- AVG Volume (30 Days)
- BMRA 95.1K
- AYTU 199.6K
- Earning Date
- BMRA 08-27-2025
- AYTU 05-14-2025
- Dividend Yield
- BMRA N/A
- AYTU N/A
- EPS Growth
- BMRA N/A
- AYTU N/A
- EPS
- BMRA N/A
- AYTU N/A
- Revenue
- BMRA $5,678,000.00
- AYTU $81,659,000.00
- Revenue This Year
- BMRA N/A
- AYTU N/A
- Revenue Next Year
- BMRA N/A
- AYTU $8.68
- P/E Ratio
- BMRA N/A
- AYTU N/A
- Revenue Growth
- BMRA 5.01
- AYTU 0.41
- 52 Week Low
- BMRA $1.93
- AYTU $0.95
- 52 Week High
- BMRA $10.16
- AYTU $2.85
- Technical
- Relative Strength Index (RSI)
- BMRA 63.63
- AYTU 71.61
- Support Level
- BMRA $3.50
- AYTU $2.30
- Resistance Level
- BMRA $4.24
- AYTU $2.72
- Average True Range (ATR)
- BMRA 0.25
- AYTU 0.14
- MACD
- BMRA 0.09
- AYTU 0.02
- Stochastic Oscillator
- BMRA 74.62
- AYTU 84.68
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.